Democritus University of Thrace (DUTH)
Μελέτη των επιπέδων της βιταμίνης D στο πλάσμα ασθενών με σύνδρομο αποφρακτικών απνοιών κατά τον ύπνο
Abstract
dc:descriptionIntroduction: Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent episodes of partial or complete upper airway obstruction during sleep. Although it is the most common breathing disorder during sleep, it often remains undiagnosed. Symptoms include snoring and breathing cessation as well as choking or gasping during sleep, while excessive daytime sleepiness (EDS) is the main daytime manifestation of OSAS.Vitamin D is a fat-soluble vitamin produced in the skin after exposure to sunlight or it is absorbed through diet. In the bloodstream, vitamin D binds to the vitamin D binding protein (VDBP) and its biological functions are expressed after the connection to its cellular receptor (VDR). In addition to regulating homeostasis of calcium and phosphorus, which constitutes its main activity, vitamin D also acts on other systems, such as the immune system and muscles, while deficient vitamin levels are associated with increased probability of developing cardiovascular disease and metabolic syndrome.Recent data support a bidirectional relationship between OSAS and serum vitamin D levels. Conditions associated with hypovitaminosis D, such as immune system disorders, systemic inflammation and myopathy, seem to favor the onset of OSAS and EDS, while obesity, a common feature of patients with sleep apnea, negatively affects vitamin D levels.Aim: The aim of the study was to determine vitamin D levels in patients with OSAS and to explore their correlation with anthropometric characteristics and sleep parameters. At the same time, the relationship between vitamin D levels with EDS and metabolic syndrome was investigated in the same patient population. Finally, we studied the possible association between VDR and VDBP gene polymorphisms and OSAS.Patients – Methods: The study population consisted of 268 subjects (223 men and 45 women) consecutively referred for sleep study, due to suspected OSAS. After obtaining a complete medical history and measuring anthropometric characteristics, all participants underwent a complete polysomnographic study for OSAS diagnosis. The presence of EDS was assessed using the Epworth sleepiness scale. The diagnosis of metabolic syndrome was set according to the criteria of the International Diabetes Federation. Respiratory function was assessed to all participants through spirometry and arterial blood gas analysis. Vitamin D [25(OH)D] levels were measured, as well as parameters regarding liver function, fasting glucose levels and lipid profile, and VDR and VDBP gene polymorphisms were also determined.Results: Subjects were divided according to apnea-hypopnea index (AHI) in two groups: control group (AHI <5 events/hour sleep, that included 52 subjects) and OSAS group (AHI ≥5 events/hour of sleep, that included 216 patients). Serum 25(OH)D levels were lower in OSAS patients (p<0.001).A negative correlation was observed between 25(OH)D levels and AHI (p=0.034), oxyhemoglobin desaturation index (p=0.010), percentage of sleep time with oxyhemoglobin saturation <90% (p<0.001) and sleep stage transitions (p=0.003). OSAS patients were also divided into 2 subgroups according to 25(OH)D levels: a subgroup with sufficient vitamin D levels [25(OH)D levels ≥20 ng/ml] and a subgroup with insufficient vitamin D levels [25(OH)D levels <20 ng/ml]. Compared to the latter, OSAS patients with sufficient 25(OH)D levels demonstrated a better sleep quality, indicated by increased duration of sleep stage 2 (p=0.047) and decreased number of sleep stage transitions (p=0.001).In order to study the relationship between vitamin D and daytime sleepiness in patients with OSAS, the latter were divided into 2 subgroups: without EDS (ESS ≤10) and with EDS (ESS >10). In the latter reduced 25(OH)D levels were observed compared with OSAS patients without EDS (p=0.046). Regression analysis demonstrated that both 25(OH)D levels (p=0.045) and AHI (p=0.05) were predictors of EDS in OSAS patients.Additionally, in order to evaluate vitamin D levels in patients with ΟSAS and metabolic syndrome (MS), a group of 107 ΟSAS patients was studied. Patients were divided in two subgroups according to the presence of MS: a subgroup of patients with OSAS and MS and a subgroup of patients with OSAS but without MS. In patients with OSAS without MS increased 25(OH)D levels were observed compared with those with OSAS and MS (p=0.012). Furthermore the group of patients with OSAS and MS was divided into two subgroups according to the metabolic score: patients with OSAS and metabolic score =3 and patients with OSAS and metabolic score >3. OSAS patients with metabolic score of 3 had increased 25(OH)D levels compared with OSAS patients with metabolic score >3 (p=0.038).Finally, VDR and VDBP gene polymorphisms were determined in 176 subjects. Subjects were divided in two groups according to AHI: group of patients with OSAS (AHI ≥5 events/hour of sleep) and control group (AHI <5 events/hour of sleep). The distribution of the 3 VDR gene genotypes (FF/Ff/ff) showed a significant difference between OSAS and healthy subjects (p=0.027). More specifically, the frequency of the FF genotype was higher in OSAS patients compared to non-apnoeic subjects (p=0.021). No differences were observed between the groups regarding distribution frequency of genotypes of the BsmI, ApaI and TaqI polymorphisms of the VDR gene, as well as the polymorphisms rs4588 and rs7041 of the VDBP gene. In OSAS patients, presence of FokI polymorphism was associated with 25(OH)D levels. Regression analysis showed that the combination of 25(OH)D levels and FokI polymorphism showed an inverse correlation with OSAS (p=0.014).Conclusions: Vitamin D levels are decreased in patients with OSAS compared to controls, suggesting an increased risk of vitamin D deficiency in this patient population. In addition, vitamin D levels are related to the severity of the disease and to indices of nocturnal hypoxemia and sleep disruption. Also, vitamin D levels were lower in patients with OSAS and EDS, highlighting the bidirectional relationship between the two conditions. Our results also indicate that patients with both OSAS and MS have significantly reduced vitamin D levels compared with patients with OSAS alone. In addition, vitamin D deficiency is more common in patients with more severe MS (metabolic score >3). Finally, FokI polymorphism of the VDR gene is associated with OSAS and vitamin D levels in these patients. Also, the combination of low vitamin D levels and FokI dominant genotype FF is associated with an increased probability of OSAS occurrence.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Archontogeorgis, Konstantinos
- Αρχοντογεώργης, Κωνσταντίνος
Subjects
dc:subject × 14- Σύνδρομο αποφρακτικών απνοιών-υποπνοιών ύπνου
- Βιταμίνη D
- Μεταβολικό σύνδρομο
- Υπερβολική ημερήσια υπνηλία
- Γενετικοί πολυμορφισμοί
- Obstructive sleep apnea syndrome
- Vitamin D
- Metabolic syndrome
- Excessive daytime sleepiness
- Genetic polymorphisms
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43448